493 related articles for article (PubMed ID: 23699667)
1. Comparison of 18F-fluoroazomycin-arabinofuranoside and 64Cu-diacetyl-bis(N4-methylthiosemicarbazone) in preclinical models of cancer.
Valtorta S; Belloli S; Sanvito F; Masiello V; Di Grigoli G; Monterisi C; Fazio F; Picchio M; Moresco RM
J Nucl Med; 2013 Jul; 54(7):1106-12. PubMed ID: 23699667
[TBL] [Abstract][Full Text] [Related]
2. Intertumoral differences in hypoxia selectivity of the PET imaging agent 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone).
Yuan H; Schroeder T; Bowsher JE; Hedlund LW; Wong T; Dewhirst MW
J Nucl Med; 2006 Jun; 47(6):989-98. PubMed ID: 16741309
[TBL] [Abstract][Full Text] [Related]
3. Assessment of regional tumor hypoxia using 18F-fluoromisonidazole and 64Cu(II)-diacetyl-bis(N4-methylthiosemicarbazone) positron emission tomography: Comparative study featuring microPET imaging, Po2 probe measurement, autoradiography, and fluorescent microscopy in the R3327-AT and FaDu rat tumor models.
O'Donoghue JA; Zanzonico P; Pugachev A; Wen B; Smith-Jones P; Cai S; Burnazi E; Finn RD; Burgman P; Ruan S; Lewis JS; Welch MJ; Ling CC; Humm JL
Int J Radiat Oncol Biol Phys; 2005 Apr; 61(5):1493-502. PubMed ID: 15817355
[TBL] [Abstract][Full Text] [Related]
4. A limited overlap between intratumoral distribution of 1-(5-fluoro-5-deoxy-α-D-arabinofuranosyl)-2-nitroimidazole and copper-diacetyl-bis[N(4)-methylthiosemicarbazone].
Furukawa T; Yuan Q; Jin ZH; Aung W; Yoshii Y; Hasegawa S; Endo H; Inoue M; Zhang MR; Fujibayashi Y; Saga T
Oncol Rep; 2015 Sep; 34(3):1379-87. PubMed ID: 26134305
[TBL] [Abstract][Full Text] [Related]
5. A comparison of the imaging characteristics and microregional distribution of 4 hypoxia PET tracers.
Carlin S; Zhang H; Reese M; Ramos NN; Chen Q; Ricketts SA
J Nucl Med; 2014 Mar; 55(3):515-21. PubMed ID: 24491409
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of hypoxic PET using (18)F-FAZA and (62)Cu-ATSM in non-small-cell lung cancer.
Kinoshita T; Fujii H; Hayashi Y; Kamiyama I; Ohtsuka T; Asamura H
Lung Cancer; 2016 Jan; 91():56-66. PubMed ID: 26711935
[TBL] [Abstract][Full Text] [Related]
7. Autoradiographic and small-animal PET comparisons between (18)F-FMISO, (18)F-FDG, (18)F-FLT and the hypoxic selective (64)Cu-ATSM in a rodent model of cancer.
Dence CS; Ponde DE; Welch MJ; Lewis JS
Nucl Med Biol; 2008 Aug; 35(6):713-20. PubMed ID: 18678357
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of 64Cu-ATSM in vitro and in vivo in a hypoxic tumor model.
Lewis JS; McCarthy DW; McCarthy TJ; Fujibayashi Y; Welch MJ
J Nucl Med; 1999 Jan; 40(1):177-83. PubMed ID: 9935074
[TBL] [Abstract][Full Text] [Related]
9. Assessing tumor hypoxia in cervical cancer by PET with 60Cu-labeled diacetyl-bis(N4-methylthiosemicarbazone).
Dehdashti F; Grigsby PW; Lewis JS; Laforest R; Siegel BA; Welch MJ
J Nucl Med; 2008 Feb; 49(2):201-5. PubMed ID: 18199612
[TBL] [Abstract][Full Text] [Related]
10. Enhancing targeted radiotherapy by copper(II)diacetyl- bis(N4-methylthiosemicarbazone) using 2-deoxy-D-glucose.
Aft RL; Lewis JS; Zhang F; Kim J; Welch MJ
Cancer Res; 2003 Sep; 63(17):5496-504. PubMed ID: 14500386
[TBL] [Abstract][Full Text] [Related]
11. Double-tracer autoradiography with Cu-ATSM/FDG and immunohistochemical interpretation in four different mouse implanted tumor models.
Tanaka T; Furukawa T; Fujieda S; Kasamatsu S; Yonekura Y; Fujibayashi Y
Nucl Med Biol; 2006 Aug; 33(6):743-50. PubMed ID: 16934693
[TBL] [Abstract][Full Text] [Related]
12. Retention of the radiotracers 64Cu-ATSM and 64Cu-PTSM in human and murine tumors is influenced by MDR1 protein expression.
Liu J; Hajibeigi A; Ren G; Lin M; Siyambalapitiyage W; Liu Z; Simpson E; Parkey RW; Sun X; Oz OK
J Nucl Med; 2009 Aug; 50(8):1332-9. PubMed ID: 19617332
[TBL] [Abstract][Full Text] [Related]
13. Tumor uptake of copper-diacetyl-bis(N(4)-methylthiosemicarbazone): effect of changes in tissue oxygenation.
Lewis JS; Sharp TL; Laforest R; Fujibayashi Y; Welch MJ
J Nucl Med; 2001 Apr; 42(4):655-61. PubMed ID: 11337556
[TBL] [Abstract][Full Text] [Related]
14. 64Cu-ATSM Reflects pO2 Levels in Human Head and Neck Cancer Xenografts but Not in Colorectal Cancer Xenografts: Comparison with 64CuCl2.
Li F; Jørgensen JT; Forman J; Hansen AE; Kjaer A
J Nucl Med; 2016 Mar; 57(3):437-43. PubMed ID: 26585061
[TBL] [Abstract][Full Text] [Related]
15. Investigation into 64Cu-labeled Bis(selenosemicarbazone) and Bis(thiosemicarbazone) complexes as hypoxia imaging agents.
McQuade P; Martin KE; Castle TC; Went MJ; Blower PJ; Welch MJ; Lewis JS
Nucl Med Biol; 2005 Feb; 32(2):147-56. PubMed ID: 15721760
[TBL] [Abstract][Full Text] [Related]
16. Application of 62Cu-diacetyl-bis (N4-methylthiosemicarbazone) PET imaging to predict highly malignant tumor grades and hypoxia-inducible factor-1α expression in patients with glioma.
Tateishi K; Tateishi U; Sato M; Yamanaka S; Kanno H; Murata H; Inoue T; Kawahara N
AJNR Am J Neuroradiol; 2013 Jan; 34(1):92-9. PubMed ID: 22700754
[TBL] [Abstract][Full Text] [Related]
17. Copper-64-diacetyl-bis(N(4)-methylthiosemicarbazone) pharmacokinetics in FaDu xenograft tumors and correlation with microscopic markers of hypoxia.
McCall KC; Humm JL; Bartlett R; Reese M; Carlin S
Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):e393-9. PubMed ID: 22727887
[TBL] [Abstract][Full Text] [Related]
18. Nitroimidazole conjugates of bis(thiosemicarbazonato)64Cu(II) - Potential combination agents for the PET imaging of hypoxia.
Bonnitcha PD; Bayly SR; Theobald MB; Betts HM; Lewis JS; Dilworth JR
J Inorg Biochem; 2010 Feb; 104(2):126-35. PubMed ID: 19932509
[TBL] [Abstract][Full Text] [Related]
19. Basic characterization of 64Cu-ATSM as a radiotherapy agent.
Obata A; Kasamatsu S; Lewis JS; Furukawa T; Takamatsu S; Toyohara J; Asai T; Welch MJ; Adams SG; Saji H; Yonekura Y; Fujibayashi Y
Nucl Med Biol; 2005 Jan; 32(1):21-8. PubMed ID: 15691658
[TBL] [Abstract][Full Text] [Related]
20. Intra-tumoral distribution of (64)Cu-ATSM: a comparison study with FDG.
Obata A; Yoshimoto M; Kasamatsu S; Naiki H; Takamatsu S; Kashikura K; Furukawa T; Lewis JS; Welch MJ; Saji H; Yonekura Y; Fujibayashi Y
Nucl Med Biol; 2003 Jul; 30(5):529-34. PubMed ID: 12831991
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]